

www.nhslothian.scot

Date 24/12/2025
 Your Ref
 Our Ref 10894

Enquiries to Richard Mutch
 Extension 35687
 Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to prescribing

Question:

1. Does the aseptic unit at your organisation employ vial-sharing for durvalumab (Imfinzi)?

Answer:

| | Yes / No |
|---|----------|
| Employs vial-sharing for durvalumab (Imfinzi) | No |

Question:

2. In the past 12 months was **durvalumab (Imfinzi)** administered as the following actual doses?

Answer:

| | Yes / No |
|------------|----------|
| 1,500 mg | Yes |
| 10 mg / kg | Yes |
| 20 mg / kg | No |

Question:

3. In the past 12 months was **durvalumab (Imfinzi)** made up for administration to patients at an on-site aseptic unit?

Answer:

| | Yes / No |
|----------------------|----------|
| On-site aseptic unit | Yes |

Question:

4. In the past 12 months was **durvalumab (Imfinzi)** made up for administration to patients at an external aseptic unit?

Answer:

| | Yes / No |
|---|----------|
| External aseptic unit – based at another hospital | No |
| External aseptic unit – from a third supplier | No |

Question:

5. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of **durvalumab (Imfinzi)** in the past 12 months.

Answer:

Not applicable.

Question:

6. How many patients were treated with durvalumab (Imfinzi) between Jul and Sep 2025, or latest 3 months for which data is available?

Answer:

| |
|--------------------|
| Number of patients |
| 19 |

Question:

7. How many patients were treated with **durvalumab (Imfinzi)** within each of bands in the national dose banding table between Jul and Sep 2025?

Answer:

| Band range (mg) | | | Band dose (mg) | Number of patients |
|-----------------|----------|----------|----------------|--------------------|
| From ≥ | To (A) < | To (B) ≤ | | |
| 189.74 | 219.09 | 219.08 | 200 | 0 |
| 219.09 | 268.33 | 268.32 | 240 | 0 |
| 268.33 | 328.63 | 328.62 | 300 | 0 |

| | | | | |
|---------|---------|---------|------|----|
| 328.63 | 388.84 | 388.83 | 360 | 0 |
| 388.84 | 458.26 | 458.25 | 420 | 0 |
| 458.26 | 547.72 | 547.71 | 500 | 0 |
| 547.72 | 648.07 | 648.06 | 600 | 0 |
| 648.07 | 771.36 | 771.35 | 700 | 0 |
| 771.36 | 921.95 | 921.94 | 850 | 0 |
| 921.95 | 1058.30 | 1058.29 | 1000 | 0 |
| 1058.30 | 1178.47 | 1178.46 | 1120 | 0 |
| 1178.47 | 1363.82 | 1363.81 | 1240 | 0 |
| 1363.82 | 1596.87 | 1596.86 | 1500 | 19 |
| 1596.87 | 1843.91 | 1843.90 | 1700 | 0 |

<https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b02/chemotherapy-dose-banding/>

Question:

8. How many patients were treated with **durvalumab (Imfinzi)** for the following types of cancer between Jul and Sep 2025, or latest 3 months for which data is available?

Answer:

| Type of Cancer | Number of patients |
|--------------------------------|--------------------|
| Non-small Cell Lung Cancer | 12 |
| Biliary Tract Cancer | 7 |
| Small Cell Lung Cancer | 0 |
| Hepatocellular Carcinoma | 0 |
| Endometrial Cancer | 0 |
| Muscle Invasive Bladder Cancer | 0 |
| Other (please specify) | 0 |

Question:

9. Does the aseptic unit employ vial-sharing for **trastuzumab deruxtecan (Enhertu)**?

Answer:

| | Yes / No |
|---|----------|
| Employs vial-sharing for trastuzumab deruxtecan (Enhertu) | No |

Question:

10. In the past 12 months was **trastuzumab deruxtecan (Enhertu)** administered as the following actual doses?

Answer:

| | Yes / No |
|---------------|----------|
| 6.4 mg / kg | 0 |
| 5.4 mg / kg | 26 |
| 4.4 mg / kg | 11 |
| < 4.4 mg / kg | 8 |

Question:

11. In the past 12 months was **trastuzumab deruxtecan (Enhertu)** made up for administration to patients at an on-site aseptic unit?

Answer:

| | Yes / No |
|----------------------|----------|
| On-site aseptic unit | Yes |

Question:

12. In the past 12 months was **trastuzumab deruxtecan (Enhertu)** made up for administration to patients at an external aseptic unit?

Answer:

| | Yes / No |
|---|----------|
| External aseptic unit – based at another hospital | No |
| External aseptic unit – from a third supplier | No |

Question:

13. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of **trastuzumab deruxtecan (Enhertu)** in the past 12 months.

Answer:

Not applicable.

Question:

14. How many patients were treated with **trastuzumab deruxtecan (Enhertu)** within each of bands in the national dose banding table between Jul and Sep 2025?

Answer:

| Band Range (mg) | | | Band Dose (mg) | Number of patients |
|-----------------|----------|----------|----------------|--------------------|
| From ≥ | To (A) < | To (B) ≤ | | |
| 95.92 | 103.92 | 103.91 | 100.00 | 0 |
| 103.92 | 111.93 | 111.92 | 108.00 | 0 |
| 111.93 | 121.85 | 121.84 | 116.00 | 0 |
| 121.85 | 135.77 | 135.76 | 128.00 | 0 |
| 135.77 | 151.79 | 151.78 | 144.00 | 0 |
| 151.79 | 169.71 | 169.70 | 160.00 | 0 |
| 169.71 | 189.74 | 189.73 | 180.00 | 0 |
| 189.74 | 209.76 | 209.75 | 200.00 | 5< |
| 209.76 | 229.78 | 229.77 | 220.00 | 5< |
| 229.78 | 249.80 | 249.79 | 240.00 | 5< |
| 249.80 | 269.82 | 269.81 | 260.00 | 5< |
| 269.82 | 289.83 | 289.82 | 280.00 | 5< |
| 289.83 | 309.84 | 309.83 | 300.00 | 7 |
| 309.84 | 339.41 | 339.40 | 320.00 | 5< |
| 339.41 | 379.47 | 379.46 | 360.00 | 7 |
| 379.47 | 419.52 | 419.51 | 400.00 | 5< |
| 419.52 | 459.57 | 459.56 | 440.00 | 5< |
| 459.57 | 489.90 | 489.89 | 480.00 | 0 |

| | | | | |
|--------|--------|--------|--------|----|
| 489.90 | 519.62 | 519.61 | 500.00 | 5< |
| 519.62 | 569.21 | 569.20 | 540.00 | 5< |
| 569.21 | 619.68 | 619.67 | 600.00 | 0 |
| 619.68 | 669.33 | 669.32 | 640.00 | 0 |
| 669.33 | 719.72 | 719.71 | 700.00 | 0 |
| 719.72 | 769.42 | 769.41 | 740.00 | 0 |
| 769.42 | 848.53 | 848.52 | 800.00 | 0 |
| 848.53 | 948.68 | 948.67 | 900.00 | 0 |

<https://www.england.nhs.uk/commissioning/spec-services/hpc-crg/group-b/b02/chemotherapy-dose-banding/>

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
 Cc: Chief Executive